A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
Authors:
- 28 September 2013
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 31 (6) , 1530-1538
Abstract
Summary Background The kinesin spindle protein Eg5 is involved in mitosis, and its inhibition promotes mitotic arrest. EMD 534085, a potent, reversible Eg5 inhibitor, demonstrated significant preclinical antitumor activity. Methods This first-in-man, single-center, open-label, phase I dose-escalation study (3 + 3 design) investigated EMD 534085 safety, pharmacokinetics and antitumor activity in refractory solid tumors, Hodgkin’s lymphoma, or non-Hodgkin’s lymphoma. EMD 534085 (starting dose 2 mg/m2/day) was administered intravenously every 3 weeks. Doses were escalated in 100 % steps in successive cohorts of 3 patients until grade 2 toxicity occurred, followed by 50 % until the first dose-limiting toxicity (DLT) arose. If Results Forty-four patients received EMD 534085. Median treatment duration was 43 days (range, 21–337). Thirty-eight patients (86 %) received ≥2 cycles. DLTs were grade 4 neutropenia (1 patient each at 108 and 135 mg/m2/day), and grade 3 acute coronary syndrome with troponin I elevation (1 patient at 135 mg/m2/day). The maximum tolerated dose (MTD) was 108 mg/m2/day. The most common treatment-related adverse events were asthenia (50 %) and neutropenia (32 %). EMD 534085 appeared to have linear pharmacokinetics. Increase in phospho-histone H3 positive cells in paired pre- and on-treatment biopsies showed evidence of target modulation. No complete or partial responses were observed. Best response was stable disease in 23 patients (52 %). Conclusions EMD 534085 appeared to be well tolerated; MTD was 108 mg/m2/day. Preliminary antitumor results suggested limited activity in monotherapy.Keywords
This publication has 21 references indexed in Scilit:
- Breaking the ties that bind: New advances in centrosome biologyJournal of Cell Biology, 2012
- Rapid induction of apoptosis during Kinesin-5 inhibitor-induced mitotic arrest in HL60 cellsCancer Letters, 2011
- A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumorsInvestigational New Drugs, 2011
- A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II doseCancer Chemotherapy and Pharmacology, 2010
- A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)Investigational New Drugs, 2008
- A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trialInvestigational New Drugs, 2007
- Microtubule-Associated Proteins as Targets in Cancer ChemotherapyClinical Cancer Research, 2007
- Mechanistic Analysis of the Mitotic Kinesin Eg5Journal of Biological Chemistry, 2004
- Microtubules as a target for anticancer drugsNature Reviews Cancer, 2004
- Mitotic spindle organization by a plus-end-directed microtubule motorNature, 1992